Literature DB >> 9470422

Cyanotic Raynaud's phenomenon with conventional but not with liposomal amphotericin B: three case reports.

B Zernikow1, G Fleischhack, C Hasan, U Bode.   

Abstract

Despite its common adverse effects intravenous (i.v.) amphotericin B is an indispensable antifungal drug in childhood oncology. We report here on three cases of painful cyanotic Raynaud's phenomenon after i.v. administration or inhalation of amphotericin B. A liposomal i.v. preparation of amphotericin B was well tolerated by the infants. Spasms of peripheral vessels mediated by thromboxane A2 could be responsible for the Raynaud's phenomenon. Hence, inhibitors of prostaglandin synthesis are suggested for therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9470422     DOI: 10.1111/j.1439-0507.1997.tb00250.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  2 in total

Review 1.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

2.  Amphotericin B liposome-induced acrocyanosis and elevated serum creatinine.

Authors:  Xiangcai Zhang; Jie Jin; Chuang Cai; Ren Zheng; Yu Wang; Yingying Xu
Journal:  Indian J Pharmacol       Date:  2016 May-Jun       Impact factor: 1.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.